Treasa Grangier
Family · Jeffersonville, INNPI 1821340506
Payments from drug & device makers
Across 367 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$750
- Otsuka America Pharmaceutical, Inc.$357
- GSK$321
- Amgen$317
- Lilly USA, LLC$284
- plus $2K from 36 others
What the payments were for
- Food & beverage$5,946100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$124
How this compares
$5,958 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 48 | $64,889 |
| LinzessLinaclotide | 78 | $61,953 |
| MounjaroTirzepatide | 41 | $44,657 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $36,564 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 46 | $32,887 |
| EliquisApixaban | 40 | $25,408 |
| VraylarCariprazine Hcl | 12 | $15,259 |
| FarxigaDapagliflozin Propanediol | 22 | $15,004 |
| Topiramate ErTopiramate | 13 | $13,544 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,612 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,276 |
| XareltoRivaroxaban | 11 | $9,197 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 415 | $7,479 |
| MovantikNaloxegol Oxalate | 15 | $6,100 |
| Pregabalin | 32 | $4,963 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Vraylar | $1,470 | $77,21290 claims |
| Novo NordiskOzempic | $216 | $64,88948 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $321 | $49,17683 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $750 | $47,89168 claims |
| Lilly USA, LLCMounjaro | $284 | $44,65741 claims |
| PfizerEliquis | $80 | $25,40840 claims |
| Axsome Therapeutics, Inc.Auvelity | $240 | $11,27611 claims |
| Johnson & JohnsonXarelto | $17 | $9,19711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Jeffersonville
- Rhonda StameyJeffersonville$28K
- Michelle VissingJeffersonville$18K
- Stacy GarciaJeffersonville$17K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.